13.11.2014 Views

Haematologica 2003 - Supplements

Haematologica 2003 - Supplements

Haematologica 2003 - Supplements

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

176<br />

Pro-inflammatory and angiogenic cytokines in multiple<br />

myeloma patients<br />

Jurczyszyn A., Wolska-Smoleñ T., Zawirska D.,Fedak D.,<br />

Naskalski J., Skotnicki A.B.<br />

1. Chair and Department of Hematology, Jagiellonian University,<br />

Cracow, Poland.2. Clinical Biochemistry Department, Jagiellonian<br />

University, Cracow, Poland.<br />

Interleukin-6 (IL-6) is a major growth and survival factor for<br />

myeloma cells and may also play a role in the development of the<br />

bone disease. A soluble form of the IL-6R (sIL-6R) is unusual<br />

amongst soluble cytokine receptors, because it retains biological<br />

activity and acts as an agonist by binding IL-6, associating with<br />

gp130 and allowing signal transduction.<br />

Recent reports pointed that bone marrow angiogenesis is<br />

increased in multiple myeloma patients. It prompted us to<br />

examine plasma concentrations of several cytokines and to<br />

elucidate if any their clinical significance.<br />

We have measured the serum concentration of interleukin-6 (IL-<br />

6), soluble receptor for IL-6 (sIL-6R), vascular endothelial<br />

growth factor (VEGF), soluble vascular endothelial growth factor<br />

receptor (KDR/sVEGF-R2), basic fibroblast growth factor (b-<br />

FGF), tumor growth factor beta-1 (TGF-beta1) and hepatocyte<br />

growth factor (HGF) in 76 patients with multiple myeloma (MM)<br />

and 35 healthy subjects. The circulating serum levels of the<br />

cytokines were measured by Quantikine kit (R&D Systems Inc.,<br />

Minneapolis). Plasma were collected at diagnosis - 29 cases and<br />

during treatment (from 1 month up to 8 years) - 23 cases with<br />

good response to therapy and others with relapsed MM. All<br />

samples were kept frozen at -20°C. Results are reported as<br />

median values (range).<br />

Examined groups<br />

Multiple myeloma Control group<br />

Measured<br />

group<br />

p<br />

cytokines<br />

n x ± SD (minmaxmax)<br />

n x ± SD (min-<br />

IL-6<br />

13,65 ± 42,61 1,04 ± 1,12<br />

65<br />

35<br />

0,006<br />

(pg/ml)<br />

(0 –251,13) (0–3,04)<br />

sIL-6R<br />

37,1 ± 14,2 25,3 ± 6,4<br />

65<br />

35<br />

0,003<br />

(ng/ml)<br />

(15,7 – 78,3) (14,6–38,4)<br />

VEGF<br />

56,8 ± 46,7 49,9 ± 49,9<br />

65<br />

35<br />

NS<br />

(pg/ml)<br />

(5 – 219)<br />

(0 – 176,3)<br />

s VEGF- 7518 ± 2119 8725±1281<br />

65<br />

35<br />

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!